Does the SLC30A8 rs13266634 CC genotype increase type 2 diabetes risk by impairing insulin secretion?

The SLC30A8 rs13266634 polymorphism is one of the most robustly validated genetic markers for type 2 diabetes (T2D) risk. Extensive research confirms that individuals carrying the CC genotype possess a variant of the ZnT8 transporter that fundamentally alters insulin processing within the pancreas.

Clinical and effectiveness evidence

The association between the SLC30A8 rs13266634 CC genotype and type 2 diabetes has been consistently replicated across diverse global populations, including European, East Asian, and South Asian cohorts.

• Risk Magnitude: Large-scale meta-analyses of genome-wide association studies (GWAS) show that the C-allele (the risk allele) is associated with an approximately 12% to 33% increased risk of T2D per allele (OR ~1.12–1.33).
• Secretion Deficits: Clinical assessments using hyperglycemic clamps and oral glucose tolerance tests (OGTT) demonstrate that non-diabetic carriers of the CC genotype exhibit significantly lower first-phase insulin secretion and a reduced insulinogenic index compared to those with the protective TT genotype.

Mechanistic explanations

The rs13266634 polymorphism results in an amino acid substitution (Arg325Trp) in the C-terminal domain of the ZnT8 protein, which is exclusively localized to the insulin secretory granules of pancreatic beta-cells.

• Zinc Transport: ZnT8 is responsible for pumping zinc ions from the cytoplasm into insulin granules. The CC genotype (encoding Arginine at position 325) produces a transporter with altered kinetics. Specifically, the Arg325 variant is often associated with higher transport activity (gain-of-function) compared to the Trp325 variant.
• Insulin Maturation: Zinc is required for insulin molecules to form stable hexamers and crystallize for storage. Dysregulated zinc transport—whether excessive or insufficient—disrupts this maturation process, leading to less stable insulin storage and impaired rapid-release dynamics during glucose stimulation.

Clinical implications

The risk conferred by the SLC30A8 CC genotype is specific to beta-cell function (insulin secretion) rather than insulin resistance. This distinguishes it from other T2D risk factors like obesity or sedentary lifestyle, suggesting that for these individuals, the primary physiological challenge is a "failure to secrete" rather than a "failure to respond."

Bottom line

The SLC30A8 rs13266634 CC genotype is a scientifically supported risk factor for type 2 diabetes. It directly alters ZnT8-mediated zinc transport in the pancreas, leading to impaired insulin crystallization and a diminished capacity for glucose-stimulated insulin secretion.